Guardant Health Q4 2025 Earnings Call Summary

1Key Financial Results and Metrics

Q4 Revenue: $281 million, up 39% year-over-year.

Full Year Revenue: $982 million, a 33% increase year-over-year.

Oncology Revenue: $190 million in Q4, a 30% increase; full year at $683.6 million, up 26%.

Oncology Test Volume: Approximately 79,000 tests in Q4, a 38% increase.

Biopharma and Data Revenue: $54 million in Q4, up 9%; full year at $210 million, an 18% increase.

Screening Revenue: $35 million in Q4 from approximately 38,000 Shield tests; full year at $79.7 million from 87,000 tests.

Non-GAAP Gross Margin: Improved to 66% in Q4 from 63% year-over-year.

Adjusted EBITDA Loss: Improved to $64.9 million in Q4 from $78.4 million in the prior year.

Free Cash Flow Burn: $233 million for the year, with expectations for improvement in 2026.

2Strategic Updates and Business Highlights

Product Innovations: Launched new applications for Guardant360 and expanded Shield to include multi-cancer detection results.

Medicare Coverage: Received Medicare coverage for colorectal cancer (CRC) surveillance, enhancing the adoption of Reveal.

Commercial Expansion: Increased sales force to approximately 300 reps and established partnerships with Quest Diagnostics and PathGroup to broaden market reach.

Acquisition: Acquired MetaSight Diagnostics for $59 million, aimed at enhancing the oncology product portfolio.

3Forward Guidance and Outlook

2026 Revenue Guidance: Expected in the range of $1.25 billion to $1.28 billion, reflecting growth of 27% to 30%.

Oncology Revenue Growth: Forecasted at 25% to 27% with a volume growth of approximately 30%.

Screening Revenue: Expected between $162 million to $174 million, driven by 210,000 to 225,000 tests.

Gross Margin Expectations: Non-GAAP gross margin projected to be 64% to 65% for 2026.

Cash Flow: Anticipated free cash flow burn of $185 million to $195 million, with the core business expected to be free cash flow positive.

4Bad News, Challenges, or Points of Concern

Market Competition: Increased competition in the multi-cancer detection space, with recent data from competitors raising concerns about market dynamics.

Regulatory Risks: Uncertainty surrounding the timing and success of FDA submissions for new tests, including the potential for concurrent ordering of tissue and blood tests.

ASP Decline: Guidance indicates a potential decrease in average selling prices (ASP) for Shield due to a shift in demand from Medicare to commercial populations.

Screening Burn: Continued high investment in screening may lead to significant cash burn, with expectations of $220 million in 2026.

5Notable Q&A Insights

Reveal Therapeutic Monitoring: Management expressed optimism about the synergy between Reveal and Guardant360, particularly in therapy monitoring, which could drive future growth.

Shield Demand: Demand is primarily from previously unscreened patients, with a focus on closing care gaps. The company is cautious about overestimating growth based on early performance.

Commercial Strategy: Plans for direct-to-consumer campaigns in 2026 were discussed, alongside the incentivization of Quest sales reps to promote Shield.

Regulatory Strategy: The company is optimistic about the potential for multi-cancer detection tests following recent legislative developments, although they do not expect immediate financial impact. This summary encapsulates the key elements from Guardant Health's Q4 2025 earnings call, providing a balanced view of their financial performance, strategic initiatives, future outlook, and challenges faced.